All In Biotech

Drug Trial Radar · NCT06100276

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

A Phase 1/2, Multicenter, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS).

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Aug 1, 2024

Primary completion

Dec 30, 2030

Study completion Nov 30, 2031

Sponsor

Lead sponsor
UniQure Biopharma B.V.Industry
Sponsor type
Industry
First posted
Oct 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is the study of AMT-162 in Participants with SOD1-ALS and is designed to evaluate the safety, tolerability, and exploratory efficacy of intrathecally administered gene therapy AMT-162. AMT-162-001 is a Phase 1/2, multi-center, single ascending dose study.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • AMT-162Drug

    AMT-162, the investigational product (IP), is a nonreplicating, rep/cap-deleted, self-complementary Recombinant adeno-associated virus (rAAV) vector based on adeno-associated virus (AAV) serotype rh10 and contains complementary deoxyribonucleic acid (cDNA) encoding an artificial miRNA targeting the SOD1 gene.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of ascending doses of intrathecally administered AMT-162 in Participants with SOD1-ALSTime frame: up to 5 years

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona

  • University of California Irvine

    Irvine, California

  • California Pacific Medical Center

    San Francisco, California

  • Mayo Clinic Florida

    Jacksonville, Florida

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois

  • University of Kansas Medical Center

    Fairway, Kansas

  • Massachusetts General Hospital, Sean M. Healey and AMG Center for ALS Research

    Boston, Massachusetts

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Columbia University Irving Medical Center

    New York, New York

  • University of Pennsylvania School of Medicine

    Philadelphia, Pennsylvania

  • Norrlands Universitetssjukhus

    Umeå, Vasterbottens Ian, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.